. 2023 Jan 1;37(1):F1-F10.

doi: 10.1097/QAD.0000000000003429. Epub 2022 Nov 18.

COVID-19 vaccine immunogenicity in people with HIV

Cecilia T Costiniuk^{1

2

3}, Joel Singer^{4

5

6}, Terry Lee^{5

6}, Marc-André Langlois⁷, Corey Arnold⁷, Yannick Galipeau⁷, Judy Needham^{5

6}, Iva Kulic^{5

6}, Mohammad-Ali Jenabian⁸, Ann N Burchell⁹, Hasina Shamji^{10

11}, Catharine Chambers⁹, Sharon Walmsley¹², Mario Ostrowski¹³, Colin Kovacs¹⁴, Darrell H S Tan^{12

15

16}, Marianne Harris¹⁷, Mark Hull¹⁷, Zabrina L Brumme^{10

17}, Hope R Lapointe¹⁷, Mark A Brockman^{10

17

18}, Shari Margolese⁵, Enrico Mandarino⁵, Suzanne Samarani¹, Branka Vulesevic^{5

19}, Bertrand Lebouché^{1

2

20

21}, Jonathan B Angel^{7

19}, Jean-Pierre Routy^{1

2

22}, Curtis L Cooper¹⁹, Aslam H Anis^{4

5

6}; COVAXHIV Study Group

Affiliations

¹ Division of Infectious Diseases/Chronic Viral Illness Service, McGill University Health Centre, Royal Victoria Hospital.
² Infectious Diseases and Immunity in Global Health Research Institute of the McGill University Health Centre.
³ Department of Microbiology and Immunology, McGill University, Montreal, QC.
⁴ School of Population and Public Health, University of British Columbia.
⁵ Canadian Institutes of Health Research (CIHR) Canadian HIV Trials Network (CTN).
⁶ Centre for Health Evaluation and Outcome Sciences, St. Paul's Hospital, Vancouver, BC.
⁷ Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa.
⁸ Department of Biological Sciences, Université du Québec à Montréal, Montreal, QC.
⁹ Department of Family and Community Medicine, St Michael's Hospital, Unity Health Toronto and Dalla Lana School of Public Health, University of Toronto, Toronto, ON.
¹⁰ Faculty of Health Sciences, Simon Fraser University, Burnaby.
¹¹ British Columbia Centre for Disease Control, Vancouver, BC.
¹² Division of Infectious Diseases, Department of Medicine, University of Toronto.
¹³ Clinical Sciences Division and Department of Immunology, University of Toronto, Li Ka Shing Knowledge Institute, St. Michael's Hospital.
¹⁴ Maple Leaf Medical Clinic.
¹⁵ MAP Centre for Urban Health Solutions, St Michael's Hospital.
¹⁶ Institute of Public Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, ON.
¹⁷ British Columbia Centre for Excellence in HIV/AIDS, Vancouver.
¹⁸ Department of Molecular Biology and Biochemistry, Faculty of Science, Simon Fraser University, Burnaby, BC.
¹⁹ Division of Infectious Diseases, Department of Medicine, University of Ottawa and the Ottawa Hospital Research Institute, Ottawa, ON.
²⁰ Department of Family Medicine, McGill University.
²¹ Canadian Institutes of Health Research Strategy for Patient-Oriented Research Mentorship Chair in Innovative Clinical Trials.
²² Division of Hematology, Department of Medicine, McGill University Health Centre, Montreal, QC, Canada.

PMID: 36476452
PMCID: PMC9794000
DOI: 10.1097/QAD.0000000000003429

COVID-19 vaccine immunogenicity in people with HIV

Cecilia T Costiniuk et al. AIDS. 2023.

. 2023 Jan 1;37(1):F1-F10.

doi: 10.1097/QAD.0000000000003429. Epub 2022 Nov 18.

Authors

Affiliations

¹ Division of Infectious Diseases/Chronic Viral Illness Service, McGill University Health Centre, Royal Victoria Hospital.
² Infectious Diseases and Immunity in Global Health Research Institute of the McGill University Health Centre.
³ Department of Microbiology and Immunology, McGill University, Montreal, QC.
⁴ School of Population and Public Health, University of British Columbia.
⁵ Canadian Institutes of Health Research (CIHR) Canadian HIV Trials Network (CTN).
⁶ Centre for Health Evaluation and Outcome Sciences, St. Paul's Hospital, Vancouver, BC.
⁷ Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa.
⁸ Department of Biological Sciences, Université du Québec à Montréal, Montreal, QC.
⁹ Department of Family and Community Medicine, St Michael's Hospital, Unity Health Toronto and Dalla Lana School of Public Health, University of Toronto, Toronto, ON.
¹⁰ Faculty of Health Sciences, Simon Fraser University, Burnaby.
¹¹ British Columbia Centre for Disease Control, Vancouver, BC.
¹² Division of Infectious Diseases, Department of Medicine, University of Toronto.
¹³ Clinical Sciences Division and Department of Immunology, University of Toronto, Li Ka Shing Knowledge Institute, St. Michael's Hospital.
¹⁴ Maple Leaf Medical Clinic.
¹⁵ MAP Centre for Urban Health Solutions, St Michael's Hospital.
¹⁶ Institute of Public Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, ON.
¹⁷ British Columbia Centre for Excellence in HIV/AIDS, Vancouver.
¹⁸ Department of Molecular Biology and Biochemistry, Faculty of Science, Simon Fraser University, Burnaby, BC.
¹⁹ Division of Infectious Diseases, Department of Medicine, University of Ottawa and the Ottawa Hospital Research Institute, Ottawa, ON.
²⁰ Department of Family Medicine, McGill University.
²¹ Canadian Institutes of Health Research Strategy for Patient-Oriented Research Mentorship Chair in Innovative Clinical Trials.
²² Division of Hematology, Department of Medicine, McGill University Health Centre, Montreal, QC, Canada.

PMID: 36476452
PMCID: PMC9794000
DOI: 10.1097/QAD.0000000000003429

Erratum in

COVID-19 vaccine immunogenicity in people with HIV: Erratum.
[No authors listed] [No authors listed] AIDS. 2023 Mar 1;37(3):559. doi: 10.1097/01.aids.0000919260.32406.0b. AIDS. 2023. PMID: 36695370 Free PMC article. No abstract available.

Abstract

Objectives: Many vaccines require higher/additional doses or adjuvants to provide adequate protection for people with HIV (PWH). Our objective was to compare COVID-19 vaccine immunogenicity in PWH to HIV-negative individuals.

Design: In a Canadian multi-center prospective, observational cohort of PWH receiving at least two COVID-19 vaccinations, we measured vaccine-induced immunity at 3 and 6 months post 2nd and 1-month post 3rd doses.

Methods: The primary outcome was the percentage of PWH mounting vaccine-induced immunity [co-positivity for anti-IgG against SARS-CoV2 Spike(S) and receptor-binding domain proteins] 6 months post 2nd dose. Univariable and multivariable logistic regressions were used to compare COVID-19-specific immune responses between groups and within subgroups.

Results: Data from 294 PWH and 267 controls were analyzed. Immunogenicity was achieved in over 90% at each time point in both groups. The proportions of participants achieving comparable anti-receptor-binding domain levels were similar between the group at each time point. Anti-S IgG levels were similar by group at month 3 post 2nd dose and 1-month post 3rd dose. A lower proportion of PWH vs. controls maintained vaccine-induced anti-S IgG immunity 6 months post 2nd dose [92% vs. 99%; odds ratio: 0.14 (95% confidence interval: 0.03, 0.80; P = 0.027)]. In multivariable analyses, neither age, immune non-response, multimorbidity, sex, vaccine type, or timing between doses were associated with reduced IgG response.

Conclusion: Vaccine-induced IgG was elicited in the vast majority of PWH and was overall similar between groups. A slightly lower proportion of PWH vs. controls maintained vaccine-induced anti-S IgG immunity 6 months post 2nd dose demonstrating the importance of timely boosting in this population.

Trial registration: ClinicalTrials.gov NCT04894448.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

**Fig. 1**
*Study profile:* Total of 1377 participants (375 HIV+ and 1002 HIV−) from two observational cohorts were assessed for the study.

See this image and copyright information in PMC

References

1. Tesoriero JM, Swain CE, Pierce JL, Zamboni L, Wu M, Holtgrave DR, et al. COVID-19 outcomes among persons living with or without diagnosed HIV infection in New York state. JAMA Netw Open 2021; 4:e2037069. - PMC - PubMed
1. Weiser JK, Tie Y, Beer L, Neblett Fanfair R, Shouse RL. Racial/ethnic and income disparities in the prevalence of comorbidities that are associated with risk for severe COVID-19 among adults receiving HIV care, United States, 2014–2019. J Acquir Immune Defic Syndr 2021; 86:297–304. - PMC - PubMed
1. Crum-Cianflone NF, Sullivan E. Vaccinations for the HIV-infected adult: a review of the current recommendations, Part I. Infect Dis Ther 2017; 6:303–331. - PMC - PubMed
1. Crum-Cianflone NF, Sullivan E. Vaccinations for the HIV-infected adult: a review of the current recommendations, Part II. Infect Dis Ther 2017; 6:333–361. - PMC - PubMed
1. Bergman P, Blennow O, Hansson L, Mielke S, Nowak P, Chen P, et al. Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial. EBioMedicine 2021; 74:103705. - PMC - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

Associated data

Actions
- Search in PubMed
- Search in ClinicalTrials.gov

LinkOut - more resources

Full Text Sources
Medical
- ClinicalTrials.gov
- MedlinePlus Health Information
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

COVID-19 vaccine immunogenicity in people with HIV

Affiliations

COVID-19 vaccine immunogenicity in people with HIV

Authors

Affiliations

Erratum in

Abstract

Conflict of interest statement

Figures

References

Publication types

MeSH terms

Substances

Associated data

LinkOut - more resources

Full Text Sources

Medical

Miscellaneous